Matthew W. Davis - 10 Nov 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
Chief Development Officer
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
10 Nov 2025
Net transactions value
$0
Form type
4
Filing time
12 Nov 2025, 09:35:57 UTC
Previous filing
12 Nov 2025
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Matthew W. Chief Development Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN /s/ Lori Braender, as Attorney-In-Fact 12 Nov 2025 0002094283

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award $0 +50,000 $0.000000 50,000 10 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 10 Nov 2025 Common Stock 50,000 $5.58 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 The option will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.